Enobosarm in AR-positive, ER-positive, and HER2-Negative Adv

1. The clinical benefit rate was 32% in the 9 mg group and 29% in the 18 mg group. 2. Grade 3 or higher treatment-related adverse events occurred in 8% of the 9 mg group and 16% in the 18 mg group. Evidence Rating Level: 1 (Excellent) Study Rundown: Androgen receptors (AR) have been shown

Related Keywords

, Rating Level , Androgen Receptor , Breast Cancer , Enobosarm , Chronic Disease , Oncology ,